Fingerprint
Dive into the research topics of 'Phase i dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically